NZ622710A - Neuroendocrine tumor treatment using mtor inhibitors - Google Patents
Neuroendocrine tumor treatment using mtor inhibitorsInfo
- Publication number
- NZ622710A NZ622710A NZ622710A NZ62271006A NZ622710A NZ 622710 A NZ622710 A NZ 622710A NZ 622710 A NZ622710 A NZ 622710A NZ 62271006 A NZ62271006 A NZ 62271006A NZ 622710 A NZ622710 A NZ 622710A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mtor inhibitors
- tumor treatment
- neuroendocrine tumor
- rapamycin
- hydroxyethyl
- Prior art date
Links
- 206010052399 Neuroendocrine tumour Diseases 0.000 title 1
- 229940124302 mTOR inhibitor Drugs 0.000 title 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 title 1
- 201000011519 neuroendocrine tumor Diseases 0.000 title 1
- 206010007275 Carcinoid tumour Diseases 0.000 abstract 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
Landscapes
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0523658A GB0523658D0 (en) | 2005-11-21 | 2005-11-21 | Organic compounds |
GB0601082A GB0601082D0 (en) | 2006-01-19 | 2006-01-19 | Organic Compounds |
GB0602747A GB0602747D0 (en) | 2006-02-10 | 2006-02-10 | Organic compounds |
GB0607942A GB0607942D0 (en) | 2006-04-21 | 2006-04-21 | Organic compounds |
GB0609272A GB0609272D0 (en) | 2006-05-10 | 2006-05-10 | Organic compounds |
GB0609912A GB0609912D0 (en) | 2006-05-18 | 2006-05-18 | Organic compounds |
EP06120660 | 2006-09-14 | ||
NZ604127A NZ604127A (en) | 2005-11-21 | 2006-11-20 | Neuroendocrine tumor treatment using mtor inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ622710A true NZ622710A (en) | 2015-08-28 |
Family
ID=54014420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ622710A NZ622710A (en) | 2005-11-21 | 2006-11-20 | Neuroendocrine tumor treatment using mtor inhibitors |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ622710A (en) |
-
2006
- 2006-11-20 NZ NZ622710A patent/NZ622710A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL191475A (en) | Use of 40-o-(2-hydroxyethyl)-rapamycin for the manufacture of a medicament for the treatment of pancreatic neuroendocrine tumors | |
MX2009006779A (en) | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors. | |
IL182423A0 (en) | Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer | |
MY148491A (en) | FUSED BICYCLIC mTOR INHIBITORS | |
EP2046973A4 (en) | For the identification, assessment, and treatment of patients with cancer therapy | |
HK1140141A1 (en) | Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
MY146111A (en) | Acylaminopyrazoles as fgfr inhibitors | |
TW200738725A (en) | Unsaturated mTOR inhibitors | |
EP2759302A3 (en) | 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour | |
EP1720576A4 (en) | Photodynamic therapy for the treatment of acne | |
HK1120441A1 (en) | Drugs for treatment of ovarian cancer | |
EP3208615A3 (en) | Uses of labeled hsp90 inhibitors | |
WO2008031551A3 (en) | Non-neuroendocrine cancer therapy | |
DE602004027824D1 (en) | ANTITUMORAL AGENT WITH A HISTON DEACETYLASE INHIBITOR AND A TOPOISOMERASE II HEMMER | |
MX2013010770A (en) | Treatment of solid tumours. | |
NZ592825A (en) | A triazolothiadiazole inhibitor of c-met protein kinase | |
IL200410A0 (en) | Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer | |
TW200633700A (en) | Methods of using temozolomide formulation intrathecally in the treatment of cancers | |
MX2013006362A (en) | Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer. | |
UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
WO2007130501A3 (en) | Combination therapy for treatment of cancer | |
EA200901062A1 (en) | USING INHIBITORS OF SOLUBLE EPOXYDHYDROLASE FOR THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME AND RELEVANT DISORDERS | |
NZ622710A (en) | Neuroendocrine tumor treatment using mtor inhibitors | |
WO2008033368A3 (en) | Boroproline compound and cytokine combination therapy | |
EA200870603A1 (en) | TREATMENT OF TUMORS IN PEDIATRIC PATIENTS WITH ANTAGONISTS OF THE EPIDERMAL GROWTH RECEPTOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 20 NOV 2016 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20151204 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2017 BY CPA GLOBAL Effective date: 20161021 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2018 BY CPA GLOBAL Effective date: 20171019 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2019 BY CPA GLOBAL Effective date: 20181018 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2020 BY CPA GLOBAL Effective date: 20191017 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2021 BY CPA GLOBAL Effective date: 20201022 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2022 BY CPA GLOBAL Effective date: 20211022 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2023 BY CPA GLOBAL Effective date: 20221020 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2024 BY CPA GLOBAL Effective date: 20231019 |